[Erysipelas without fever or biologic inflammation during tocilizumab therapy].
Fiche publication
Date publication
avril 2017
Journal
Annales de dermatologie et de venereologie
Auteurs
Membres identifiés du Cancéropôle Est :
Pr GILLET Pierre
Tous les auteurs :
Yéléhé-Okouma M, Henry J, Petitpain N, Schmutz JL, Gillet P
Lien Pubmed
Résumé
Tocilizumab (TCZ) is a monoclonal antibody that inhibits the interleukin 6 (IL-6) signalling pathway. This treatment is extremely effective in rheumatoid arthritis (RA), which may well be accompanied by serious infections presenting misleading clinical pictures. Herein we report a case of a typical bacterial dermo-hypodermitis in a female patient treated with TCZ.
Mots clés
Cellulite, Cellulitis, Erysipelas, Interleukin-6, Interleukine-6, Polyarthrite rhumatoïde, Rheumatoid arthritis, Tocilizumab, Érysipèle
Référence
Ann Dermatol Venereol. 2017 Apr;: